Document:

Exhibit 10.2

 

COMMON STOCK PURCHASE AGREEMENT

 

THIS
COMMON STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of October 8, 2020, by and between Smart Repair Pro,
Inc., a private corporation incorporated under the laws of the State of California (“Pro”), Purex Inc., a corporation
incorporated under the laws the State of California (“Purex”)(Pro together with Purex, the “Companies”),
the stockholders of the Companies detailed in Schedule 1 attached hereto (the “Pro Stockholder”, the “Purex
Stockholders” respectively, and together the “Stockholders”) and Vicky Hacmon, ID 033847799 of 112 Rokach
Street, Ramat Gan, Israel (the “Manager”) on the one hand, and Medigus Ltd., a public company incorporated under the
laws of the State of Israel of 7A Industrial Park, P.O. Box 3030, Omer, 8496500 Israel (the “Purchaser”) on the other
hand.

 

The
parties hereby agree as follows:

 

1. Purchase
and Sale of Common Stock.

 

1.1 Purchase
and Issuance of Common Stock.

 

(a) Companies
Valuation. The valuation used for the purpose of determining the purchase price for the Pro Common Stock and the Purex Common Stock
(as each are defined herein), shall be calculated on a joint basis, and shall be equal to; (A) the Companies consolidated seller discretionary
earnings, calculated as the Companies EBITDA (as reflected in the Companies consolidated income statement for the period ended December
31, 2020 or the “Determination Period”), plus general and administrative expenses (including Manager’s
compensation expenses) and research and development expenses relating to the development of new products incurred during the Determination
Period (the “SDE”); multiplied by (B) 3.5; minus (C) the outstanding Stockholders Loan (as defined herein)(the
“Companies Valuation”). The Companies Valuation shall be allocated among the Companies such that Pro’s valuation
shall equal 88% of the Companies Valuation (the “Pro Portion” and the “Pro Valuation” respectively)
and Purex’s valuation shall be equal to 12% of the Companies Valuation (the “Purex Portion” and the “Purex
Valuation” respectively). The Companies target SDE for the annual period ended December 31, 2020 shall be $1,000,000 (the “SDE
Target”).

 

(b) Subject
to the terms and conditions of this Agreement, the Purchaser agrees to invest $1,100,000 in Pro (the “Pro Investment Amount”)
in consideration for the issuance by Pro at the Closing (as defined below) of 5,572 shares of Pro common stock (the “Pro Primary
Shares” and “Pro Common Stock” respectively) at a price per share for each Pro Primary Share of $197.4107,
reflecting a pre-money valuation on a fully diluted basis equal to the Pro Valuation, calculated based on the SDE Target (the “Pro
PPS”).

 

(c) Subject
to the terms and conditions of this Agreement, the Purchaser agrees to invest $150,00 in Purex (the “Purex Investment Amount”)
in consideration for the issuance by Purex at the Closing (as defined below) of 557 Purex common stock (the “Purex Primary Shares”
and the “Purex Common Stock” respectively) at a price per share of Purex Common Stock of $269.1964, reflecting a pre-money
valuation on a fully diluted basis equal to the Purex Valuation, calculated based on the SDE Target (the “Purex PPS”).
The shares of Pro Primary Shares together with the Purex Primary Shares issued to the Purchaser pursuant to this Agreement shall be referred
to in this Agreement as the “Primary Shares.” The Pro Investment Amount together with the Purex Investment Amount shall
be referred to in this Agreement as the “Investment Amount”).

 

     

     

    

 

1.2 Post-Closing
Adjustment.

 

(a) Within
three days of their approval and in any event as soon as practicable following the end of the Determination Period, the Companies shall
provide Purchaser with each of the Companies’s respective financial statements (including statement of income, balance sheet and
statement of cash flows) relating to the Determination Period, signed and certified by the Companies’ officers (the “Determination
Period Financials”). The Determination Period Financials shall be prepared in accordance with generally accepted accounting
principles.

 

(b) In
the event that the Companies actual SDE, as reflected in the Determination Period Financials (the “Actual SDE”) is
lower than the SDE Target, then the Companies Valuation shall be recalculated based on the formula included in Section ‎1.1(a) (the
“Adjusted Companies Valuation”) and the Pro Valuation, Pro PPS, Purex Valuation and Purex PPS shall be adjusted accordingly
(the “Adjustment”, the “Adjusted Pro Valuation”, the “Adjusted Pro PPS” the “Adjusted
Purex Valuation” and the “Adjusted Purex PPS” respectively). For the avoidance of doubt, the Closing Inventory
shall remain unchanged in the event of an Adjustment.

 

(c) Following
the Adjustment, each of the Companies shall issue to the Purchaser additional shares of Purex and Pro as follows:

 

(i) Pro
shall issue to the Purchaser such number of additional Pro Common Stock equal to (x) the number of Pro Primary Shares that would have
been issued to the Purchaser based on Adjusted Pro PPS; less (y) the number of Pro Primary Shares actually issued to Purchaser
upon the Closing (the “Pro Adjustment Shares”). The percentage received by dividing the Pro Adjustment Shares by Pro’s
issued outstanding share capital on a fully diluted basis shall be referred to herein as the “Pro Adjustment Percentage”.

 

(ii) Purex
shall issue to the Purchaser such number of additional Purex Common Stock equal to (x) the number of Purex Primary Shares that would have
been issued to the Purchaser based on the Adjusted Purex PPS; less (y) the number of Purex Primary Shares issued to Purchaser upon
the Closing (the “Purex Adjustment Shares”). The percentage received by dividing the Purex Adjustment Shares by Purex’s
issued outstanding share capital on a fully diluted basis shall be referred to herein as the “Purex Adjustment Percentage”;

 

(d) For
the avoidance of doubt, in the event that the Actual SDE is equal to or exceeds the SDE Target, no adjustment shall be affected pursuant
to this Section ‎1.2

 

1.3 Secondary
Sale of Common Stock.

 

(a) Simultaneously
with the Closing, Purchaser or its Affiliate shall purchase from the Pro Stockholder additional Pro Common Stock (the “Pro Secondary
Shares”), such that the Pro Secondary Shares and the Pro Primary Shares combined shall constitute 50.01% of Pro’s issued
and outstanding share capital on a fully diluted basis immediately after the Closing (the “Pro Post-Closing Holdings”)
or such closest attainable percentage. In the event that an Adjustment is affected following receipt by Purchaser of the Determination
Period Financials, Pro Stockholder shall have the right to repurchase from Purchaser, for no consideration, such number of Pro Secondary
Shares constituting the Pro Adjustment Percentage (the “Pro Repurchase Right” and the “Pro Repurchase Shares”
respectively).

 

    2

     

    

 

(b) Simultaneously
with the Closing, Purchaser or its Affiliate shall purchase from the Purex Stockholders additional Purex Common Stock (the “Purex
Secondary Shares”), such that the Purex Secondary Shares and the Purex Primary Shares combined shall constitute 50.01% of Purex’s
issue and outstanding share capital on a fully diluted basis immediately after the closing (the “Purex Post-Closing Holdings”)
or such closest attainable percentage. The Purex Secondary Shares shall be purchased in equal amounts from each of the Purex Stockholders.
In the event that an Adjustment is affected following receipt by Purchaser of the Determination Period Financials, Purex Stockholders
shall have the right to repurchase from Purchaser, for no consideration, such number of Purex Secondary Shares constituting the Purex
Adjustment Percentage (the “Purex Repurchase Right” and the “Purex Repurchase Shares” respectively).
Each Purex Stockholder shall have an equal Purex Repurchase Right to an equal number of Purex Repurchase Shares. The Pro Secondary Shares
and the Purex Secondary Shares shall be referred to in this Agreement as the “Secondary Shares”.

 

(c) In
the event that the Purex Repurchase Right and Pro Repurchase Right is exercised, the Parties shall take all such actions required in order
to affect the repurchase rights and duly transfer the Purex Repurchase Shares and Pro Repurchase Shares back to the Stockholders in accordance
with the terms contained herein.

 

(d) In
consideration for the Secondary Shares, Purchaser shall pay the Stockholders as follows:

 

(i) Upon
Closing, Purchaser shall pay the Stockholders aggregate cash consideration of $150,000 (the “Cash Consideration”),
allocated among the Pro Stockholder and Purex Stockholders in accordance with the Pro Portion and the Purex Portion, with the Purex Portion
of the Cash Consideration to be allocated among each Purex Stockholder in accordance with their pro rata portion of the Purex Secondary
Shares.

 

(ii) Post-Closing
and following the receipt by Purchaser of the Determination Period Financials, the implementation of the Adjustment and exercise of the
Purex and Pro Repurchase Right (if applicable), Purchaser shall issue to the Stockholders restricted American Depositary Shares of Purchaser
(“ADSs”) as follows:

 

(1) The
price per each Pro Secondary Shares shall calculated by dividing $440,000 by the number of Pro Secondary Shares (the “Pro Secondary
PPS”). In consideration for the Pro Secondary Shares, Purchaser shall issue to the Pro Stockholder ADSs of US Dollar value equal
to (x) the number of Pro Secondary Shares; minus (y) the number of Pro Repurchase shares; together multiplied by the (z)
Pro Secondary PPS (the “Pro ADS Consideration”). The price per ADS used in order to calculate the number of ADSs issued
as Pro ADS Consideration shall be equal to the higher of (i) $1, or (ii) the 60 day closing average of the ADSs on the Nasdaq Capital
Market (the “ADS Valuation”).

 

(2) The
price per each Purex Secondary Shares shall be calculated by dividing $60,000 by the number of Purex Secondary Shares (the “Purex
Secondary PPS”). In consideration for the Purex Secondary Shares, Purchaser shall issue to the Purex Stockholders ADSs, of US
Dollar value equal to (x) the number of Purex Secondary Shares; minus (y) the number of Purex Repurchase Shares; together multiplied
by the (z) Purex Secondary PPS (the “Purex ADS Consideration”). The price per ADS used in order to calculate the number
of ADSs issued as Purex ADS Consideration shall be based on the ADS valuation.

 

1.4 Milestone
Payments. The Stockholders shall be entitled to issuance of additional ADSs subject to achievement of the following milestones, in
accordance with the following allocation all in accordance with the term contained herein. As a condition to the issuance of any ADS Portion
(as defined herein), Stockholders will, prior to the planned date of issuance of such ADS Portion (the “ADS Portion Issuance
Date”), provide Purchaser with an execute addendum to this Agreement, attesting that the Stockholders representations and warranties
included in Sections ‎6.6 (Restricted Securities), ‎6.7 (Legends), ‎6.8 (Purchase Entirely for Own Account),
‎6.9 (Accredited Investor), ‎6.10 (Foreign Investors) and ‎6.11 (No General Solicitation) are true and
correct in all respects as of the applicable ADS Portion Issuance Date.

 

    3

     

    

 

(a) H1
2021 Milestone:

 

(i) Within
three days of their approval and in any event as soon as practicable following the end of the financial period ended June 30, 2021 (“H1
2021 Period”), the Companies shall provide Purchaser with each of the Companies’ respective financial statements (including
statement of income, balance sheet and statement of cash flows) relating to the H1 2021 Period, signed and certified by the Companies’
officers (the “H1 2021 Financials”). The H1 2021 Financials shall be prepared in accordance with generally accepted
accounting principles.

 

(ii) In
the event that the Companies SDE for H1 2021, in accordance with the H1 2021 Financials exceeds $600,000, the Stockholders shall be jointly
entitled to the issuance of ADSs of aggregate value equal to $375,000 based on the ADS valuation (the “H1 2021 Milestone”
and “H1 2021 Milestone ADSs” respectively). Purchaser shall issue to the Pro Stockholder and the Purex Stockholders
(with the Purex Portion divided equally among the Purex Stockholders) their respective portion of the H1 2021 Milestone ADSs in accordance
with the Pro Portion and the Purex Portion.

 

(b) 2021
Annual Milestone:

 

(i) Within
three days of their approval and in any event as soon as practicable following the end of the financial period ended December 31, 2021
(“2021 Annual Period”), the Companies shall provide Purchaser with each of the Company’s respective financial
statements (including statement of income, balance sheet and statement of cash flows) relating to 2021 Annual Period, signed and certified
by the Companies’ officers (the “2021 Annual Financials”). The 2021 Annual Financials shall be prepared in accordance
with generally accepted accounting principles.

 

(ii) In
the event that the Companies SDE for 2021 Annual Period, in accordance with the 2021 Annual Financials exceeds $1,200,000, the Stockholders
shall be jointly entitled to the issuance of ADSs of aggregate value equal to $375,000 based on the ADS valuation (the “2021
Annual Milestone” and “2021 Annual Milestone ADSs” respectively). Purchaser shall issue to the Pro Stockholder
and the Purex Stockholder their respective portion of the 2021 Annual Milestone ADSs in accordance with the Pro Portion and the Purex
Portion (with the Purex Portion to be divided equally among the Purex Stockholders. In the event that the 2021 Annual Milestone is achieved,
and the H1 2021 Milestone was not, the Stockholders shall also be entitled to receive the H1 2021 Milestone ADSs in addition to the 2021
Annual Milestone ADSs.

 

(iii) The
Pro ADS Consideration, Purex ADS Consideration, H1 2021 Milestone ADSs and 2021 Annual Milestone ADSs shall be referred to herein individually
as a “ADS Portion” and collectively be referred to as the “ADS Consideration”.

 

(iv) Set
Off. Purchaser shall be entitled to offset from any Portion of the ADS Consideration that becomes due and payable the following amounts:
(i) any amount of Losses that are indemnifiable by an Indemnitor under this Agreement; and (ii) the aggregate of all claimed amounts under
any issued Claim Notice existing as of the time of such payment.

 

    4

     

    

 

1.5 Restriction
on Resale of the ADS Consideration.

 

(a) During
the six (6) months following the cessation of any statutory restriction period applicable to the resale of the ADSs constituting each
ADS Portion of the ADS Consideration, the Stockholders shall not sell ADSs in excess of 25% of such ADS Portion.

 

(b) During
the period commencing six (6) months following the cessation of any statutory restriction applicable to each ADS Portion, such ADS Portion
may be freely resold by the Stockholders in accordance with applicable law, provided that no more than 10% of each respective ADS Portion
be traded in a single trading day.

 

2. Financing
Arrangements.

 

2.1 Stockholder
Loans. Purchaser and the Stockholders hereby acknowledge and agree that the Companies ongoing capital requirements shall be financed
by the Stockholders and Purchaser by way of stockholder loans, upon terms mutually agreed between the Parties. Within fourteen (14) days
following the Closing, Purchaser and the Stockholders shall each extend a loan of principle amount equal to $250,000 in accordance with
the terms of the loan agreement provided by Purchaser (the “Stockholder Financing” and the “Loan Agreement”
respectively). If the Companies require additional financing, the Companies shall submit notice to Purchaser and the Stockholders, detailing
the required amount and use of proceeds. Purchaser and the Stockholders shall extend a stockholder loan covering the requested amount,
up to an aggregate cap of $1,000,000, on a 60/40 basis respectively.

 

2.2 Additional
Financing. Purchaser may, upon its sole discretion, provide the Companies with additional financing of up to a principle amount of
$1 million, in order to finance the acquisition of additional online Amazon stores (the “Acquisition Financing”) provided
that such Acquisition Financing shall constitute 80% of the applicable acquisition cost, with the remaining 20% to be financed by the
Stockholders. The Acquisition Financing shall bear interest and shall be secured by a first degree fixed charge upon the Companies online
stores, a first degree fixed charge upon the Common Stock held by the Stockholders and a floating charge over the Companies’ available
cash and cash equivalents and shall be extended subject to the execution of financing and pledge agreements in the form and substance
acceptable to Purchaser . If Acquisition Financing is extended, such Acquisition Financing and any interest accrued thereon shall be repaid
prior in preference to any dividend distribution and any other indebtedness of the Companies.

 

3. Manager
Arrangements.

 

3.1 Employment.
The Manager shall enter into an employment agreement with Pro in accordance with the Offer Letter provided by Purchaser, pursuant to which
Manager will invest his full efforts and time to Pro’s activities and operations (the “Employment Agreement”).
The Employment Agreement shall provide for certain equity incentives to be determined in accordance with Purchaser’s share incentive
plan.

 

3.2 Non-Compete
& Non-Solicitation Undertaking. The Manager shall sign a non compete and non solicitation undertaking in a form acceptable to
Purchaser (the “Manager Undertaking”), which shall include an acknowledgment that he is a beneficiary of the ADS Consideration
and that execution by the Manager of the Manager Undertaking and fulfillment of his obligations thereunder is a material inducement to
the Purchaser’s obligations under this Agreement.

 

    5

     

    

 

4. Closing;
Delivery.

 

4.1 The
purchase and sale of the Primary Shares and the Secondary Shares shall take place remotely via the exchange of documents and signatures,
at such time and place as the Companies and the Purchaser mutually agree upon, orally or in writing (which time and place are designated
as the “Closing”). The Closing shall be subject to the condition included in Sections ‎8 and ‎9 below, which
conditions shall be deemed to take place simultaneously and no transaction contemplated therein shall be deemed to have been completed
or document deemed to have been delivered until all of the transactions have been completed and all of the documents have been delivered.

 

4.2 At
the Closing, the Companies and the Stockholders shall deliver to the Purchaser a certificate representing the Primary Shares and Secondary
Shares being purchased by the Purchaser at the Closing against payment of the Investment Amount therefor, by wire transfer to a bank account
designated by the Companies. For the avoidance of doubt, the Portions of the ADS Consideration shall be transferred post-Closing all in
accordance with the terms contained herein.

 

4.3 
Use of Proceeds. The Companies will use the proceeds from the sale of the Primary Shares for the repayment of outstanding loans
extended by Stockholders of an aggregate amount of $1,256,697 (the “Stockholder Loan”). Notwithstanding the above,
the Companies shall retain $100,000 of the Investment Amount for a period of twelve (12) months following the Closing for the purpose
of covering any undisclosed liabilities of the Companies.

 

4.4 Defined
Terms Used in this Agreement. In addition to the terms defined above, the following terms used in this Agreement shall be construed
to have the meanings set forth or referenced below.

 

(a) “Affiliate”
means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common
control with such Person, including, without limitation, any general partner, managing member, officer, director or trustee of such Person,
or any venture capital fund or registered investment company now or hereafter existing that is controlled by one (1) or more general partners,
managing members or investment advisers of, or shares the same management company or investment adviser with, such Person.

 

(b) “Code”
means the Internal Revenue Code of 1986, as amended.

 

(c) “Companies’
Intellectual Property” means all patents, patent applications, registered and unregistered trademarks, trademark applications,
registered and unregistered service marks, service mark applications, tradenames, copyrights, trade secrets, domain names, information
and proprietary rights and processes, software, similar or other intellectual property rights, subject matter of any of the foregoing,
tangible embodiments of any of the foregoing, licenses in, to and under any of the foregoing, and in any and all such cases that are owned
or used by the Companies in the conduct of the Companies’ business as now conducted and as presently proposed to be conducted.

 

(d) “Indemnification
Agreement” means an agreement between the Companies and the directors designated by the Purchaser to serve as members of the
board of directors of each of the Companies, to be elected pursuant to the Voting Agreements, dated as of the date of the Closing, in
the form acceptable to Purchaser.

 

(e) “Investors’
Rights Agreements” means the agreements among the Companies, the Stockholders and the Purchaser dated as of the date of the
Closing, in the form agreed upon between the Parties.

 

(f) “Key
Employee” means the Manager and any employee or consultant who either alone or in concert with others develops, invents, programs
or designs any Company Intellectual Property.

 

    6

     

    

 

(g) “Knowledge”
including the phrase “to the Companies’ knowledge” shall mean the actual knowledge after reasonable investigation
and assuming such knowledge as the individual would have as a result of the reasonable performance of his or her duties in the ordinary
course of the Manager.

 

(h) “Material
Adverse Effect” means a material adverse effect on the business, assets (including intangible assets), liabilities, financial
condition, property, prospects or results of operations of the Company.

 

(i) “Person”
means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 

(j) “Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

(k) “Transaction
Agreements” means this Agreement, the Investors’ Rights Agreements, the Voting Agreement, the Employment Agreement, the
Manager Undertaking, the Indemnification Agreements and the Loan Agreement.

 

(l) “Voting
Agreements” means the agreements among the Companies, the Purchaser and the Stockholders, dated as of the date of the Closing,
in the forms agreed upon between the Parties.

 

5. Representations
and Warranties of the Companies. The Companies hereby represent and warrant to the Purchaser that, except as set forth on the Disclosure
Schedule attached as Exhibit A to this Agreement, which exceptions shall be deemed to be part of the representations and warranties
made hereunder, the following representations are true and complete as of the date of the Closing, except as otherwise indicated. The
Disclosure Schedule shall be arranged in sections corresponding to the numbered and lettered sections contained in this Section ‎5,
and the disclosures in any section of the Disclosure Schedule shall qualify other sections in this Section ‎5 only to the extent
it is readily apparent from a reading of the disclosure that such disclosure is applicable to such other sections and a specific reference
to such other section.

 

5.1 Organization,
Good Standing, Corporate Power and Qualification. The Companies are corporations duly organized, validly existing and in good standing
under the laws of the State of California and have all requisite corporate power and authority to carry on its business as now conducted
and as presently proposed to be conducted. The Companies are duly qualified to transact business and is in good standing in each jurisdiction
in which the failure to so qualify would have a Material Adverse Effect.

 

5.2 Capitalization.

 

(a) The
authorized capital of the Companies consists, immediately prior to the Closing, of:

 

(i) With
respect to Pro, 10,000 shares of common stock, 10,000 shares of which are issued and outstanding immediately prior to the Closing (the
“Pro Common Stock”), and with respect to Purex, 1,000 shares of common stock (“Purex Common Stock”),
1,000 shares of which are issued and outstanding immediately prior to the Closing (Purex Common Stock together with Pro Common Stock,
the “Common Stock”). All of the outstanding shares of Common Stock have been duly authorized, are fully paid and nonassessable
and were issued in compliance with all applicable federal and state securities laws.

 

    7

     

    

 

(ii) The
Companies hold no Preferred Stock in its treasury.

 

(b) Reserved.

 

(c) Section
‎(c) of the Disclosure Schedule sets forth the capitalization of the Companies immediately following the Closing. There are no
outstanding options, warrants, rights (including conversion or preemptive rights and rights of first refusal or similar rights) or agreements,
orally or in writing, to purchase or acquire from the Companies any shares of Common Stock or any securities convertible into or exchangeable
for shares of Common Stock.

 

(d) The
Companies have obtained valid waivers of any rights by other parties to purchase any of the Primary Shares or Secondary Shares covered
by this Agreement.

 

5.3 Subsidiaries.
The Companies do not currently own or control, directly or indirectly, any interest in any other corporation, partnership, trust, joint
venture, limited liability company, association, or other business entity. Except as described in Section ‎5.3 of the Disclosure Schedule,
the Companies are not participants, jointly or severally, in any joint venture, partnership or similar arrangement.

 

5.4 Authorization.
All corporate action required to be taken by the Companies’ respective board of directors, Stockholders and Manager in order to
authorize the Companies to enter into the Transaction Agreements, to issue the Primary Shares and transfer the Secondary Shares at the
Closing has been taken prior to the Closing. All action on the part of the officers of the Companies necessary for the execution and delivery
of the Transaction Agreements, the performance of all obligations of the Companies under the Transaction Agreements to be performed as
of the Closing, and the issuance and delivery of the Primary Shares and transfer of the Secondary Shares has been taken prior to the Closing.
The Transaction Agreements, when executed and delivered by the Companies, the Stockholders and the Manager, shall constitute valid and
legally binding obligations of the Companies, Stockholders and Manager, enforceable against such in accordance with their respective terms
except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general
application relating to or affecting the enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability
of specific performance, injunctive relief, or other equitable remedies, or (iii) to the extent the indemnification provisions contained
in the Indemnification Agreement may be limited by applicable federal or state securities laws.

 

5.5 Valid
Issuance of Shares. The Primary Shares, when issued, sold and delivered in accordance with the terms and for the consideration set
forth in this Agreement, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions
on transfer under the Transaction Agreements and applicable state and federal securities laws. Assuming the accuracy of the representations
of the Purchasers in Section ‎6 of this Agreement and subject to the filings described in the Voting Agreement, the Primary
Shares will be issued in compliance with all applicable federal and state securities laws.

 

5.6 Governmental
Consents and Filings. Assuming the accuracy of the representations made by the Purchasers in Section ‎6 of this Agreement,
no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal,
state or local governmental authority is required on the part of the Company in connection with the consummation of the transactions contemplated
by this Agreement, except for the filing of the Restated Certificates, which will have been filed as of the Closing.

 

    8

     

    

 

5.7 Litigation.
There is no claim, action, suit, proceeding, arbitration, complaint, charge or to the Companies Knowledge, investigation pending or currently
threatened (i) against the Companies or any officer, director or Key Employee of the Companies; or (ii) to that questions the validity
of the Transaction Agreements or the right of the Companies to enter into them, or to consummate the transactions contemplated by the
Transaction Agreements; or (iii) to the Companies’ knowledge, that would reasonably be expected to have, either individually or
in the aggregate, a Material Adverse Effect. Neither the Companies nor, to the Companies’ knowledge, any of its officers, directors
or Key Employees is a party or is named as subject to the provisions of any order, writ, injunction, judgment or decree of any court or
government agency or instrumentality (in the case of officers, directors or Key Employees, such as would affect the Companies). There
is no action, suit, proceeding or investigation by the Companies pending or which the Companies intend to initiate. The foregoing includes,
without limitation, actions, suits, proceedings or investigations pending or threatened in writing (or any basis therefor known to the
Companies) involving the prior employment of any of the Companies’ employees, their services provided in connection with the Companies’
business, any information or techniques allegedly proprietary to any of their former employers or their obligations under any agreements
with prior employers.

 

5.8 Intellectual
Property.

 

(a) The
Companies own or possess or can acquire on commercially reasonable terms sufficient legal rights to all Company Intellectual Property
without any known conflict with, or infringement of, the rights of others, including prior employees or consultants. The Companies have
not received any communications alleging that the Companies have violated, or by conducting their business, would violate any of the patents,
trademarks, service marks, tradenames, copyrights, trade secrets, mask works or other proprietary rights or processes of any other Person.

 

(b) No
product or service marketed or sold (or proposed to be marketed or sold) by the Companies violates or will violate any license or infringes
or will infringe any intellectual property rights of any other party.

 

(c) Other
than with respect to commercially available software products under standard end-user object code license agreements, and except as described
in Section ‎5.8‎(c) of the Disclosure Schedule, there are no outstanding options, licenses, agreements, claims, encumbrances or
shared ownership interests of any kind relating to the Companies Intellectual Property, nor are the Companies bound by or a party to any
options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets,
software, licenses, information, proprietary rights and processes of any other Person.

 

(d) The
Companies have obtained and possess valid licenses to use all of the software programs present on the computers and other software-enabled
electronic devices that it owns or leases or that it has otherwise provided to its employees for their use in connection with the Companies’
business.

 

(e) Each
employee and consultant has assigned to the Companies all intellectual property rights he or she owns that are related to the Companies’
business as now conducted and as presently proposed to be conducted and all intellectual property rights that he, she or it solely or
jointly conceived, reduced to practice, developed or made during the period of his, her or its employment or consulting relationship with
the Companies that (i) relate, at the time of conception, reduction to practice, development, or making of such intellectual property
right, to the Companies’ business as then conducted or as then proposed to be conducted, (ii) were developed on any amount of the
Companies’ time or with the use of any of the Company’s equipment, supplies, facilities or information or (iii) resulted from
the performance of services for the Companies. It will not be necessary to use any inventions of any of its employees or consultants (or
Persons it currently intends to hire) made prior to their employment by the Companies, including prior employees or consultants.

 

    9

     

    

 

(f) Section ‎5.8(f)
of the Disclosure Schedule lists all patents, patent applications, trademarks, trademark applications, service marks, service mark applications,
tradenames, copyrights, and licenses to and under any of the foregoing, in each case owned by the Companies.

 

(g) The
Companies have not embedded, used or distributed any open source, copyleft or community source code (including but not limited to any
libraries or code, software, technologies or other materials that are licensed or distributed under any General Public License, Lesser
General Public License or similar license arrangement or other distribution model described by the Open Source Initiative at www.opensource.org,
collectively “Open Source Software”) in connection with any of its products or services that are generally available
or in development in any manner that would materially restrict the ability of the Company to protect its proprietary interests in any
such product or service or in any manner that requires, or purports to require (i) any of the Companies Intellectual Property (other
than the Open Source Software itself) be disclosed or distributed in source code form or be licensed for the purpose of making derivative
works; (ii) any restriction on the consideration to be charged for the distribution of any Companies Intellectual Property; (iii) the
creation of any obligation for the Companies with respect to Companies Intellectual Property owned by the Companies, or the grant to any
third party of any rights or immunities under Companies Intellectual Property owned by the Companies; or (iv) any other limitation,
restriction or condition on the right of the Companies with respect to its use or distribution of any Companies Intellectual Property.

 

(h) No
government funding, facilities of a university, college, other educational institution or research center, or funding from third parties
was used in the development of any Companies Intellectual Property. No Person who was involved in, or who contributed to, the creation
or development of any Company Intellectual Property, has performed services for the government, university, college, or other educational
institution or research center in a manner that would affect Companies’ rights in the Companies Intellectual Property.

 

5.9 Compliance
with Other Instruments. The Companies are not in violation or default (i) of any provisions of their Restated Certificates or Bylaws,
(ii) of any instrument, judgment, order, writ or decree, (iii) under any note, indenture or mortgage, or (iv) under any lease, agreement,
contract or purchase order to which it is a party or by which it is bound that is required to be listed on the Disclosure Schedule, or
(v) of any provision of federal or state statute, rule or regulation applicable to the Companies, the violation of which would have a
Material Adverse Effect. The execution, delivery and performance of the Transaction Agreements and the consummation of the transactions
contemplated by the Transaction Agreements will not result in any such violation or be in conflict with or constitute, with or without
the passage of time and giving of notice, either (i) a default under any such provision, instrument, judgment, order, writ, decree, contract
or agreement; or (ii) an event which results in the creation of any lien, charge or encumbrance upon any assets of the Companies’
or the suspension, revocation, forfeiture, or nonrenewal of any material permit or license applicable to the Companies’.

 

5.10 Agreements;
Actions.

 

(a) Except
for the Transaction Agreements, and except as disclosed in Section ‎5.10‎(a) of the Disclosure Schedule there are no agreements,
understandings, instruments, contracts or proposed transactions to which the Companies are a party or by which it is bound that involve
(i) obligations (contingent or otherwise) of, or payments to, the Companies in excess of $50,000, (ii) the license of any patent,
copyright, trademark, trade secret, software or other proprietary right to or from the Companies, (iii) the grant of rights to manufacture,
produce, assemble, license, market, or sell its products to any other Person that limit the Companies’ exclusive right to develop,
manufacture, assemble, distribute, market or sell its products, or (iv) indemnification by the Companies with respect to infringements
of proprietary rights.

 

    10

     

    

 

(b) Except
for the Transaction Agreements, and except as disclosed in Section ‎5.10‎(b), the Companies have not (i) declared or paid
any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock, (ii) incurred
any indebtedness for money borrowed or incurred any other liabilities individually in excess of $100,000 in the aggregate, (iii) made
any loans or advances to any Person, other than ordinary advances for business expenses, or (iv) sold, exchanged or otherwise disposed
of any of its assets or rights, other than in the ordinary course of business. For the purposes of ‎(a) and ‎(b) of this Section ‎5.10,
all indebtedness, liabilities, agreements, understandings, instruments, contracts and proposed transactions involving the same Person
(including Persons the Company has reason to believe are affiliated with each other) shall be aggregated for the purpose of meeting the
individual minimum dollar amounts of such section.

 

(c) The
Companies are not guarantors or indemnitors of any indebtedness of any other Person.

 

5.11 Certain
Transactions.

 

(a) Other
than (i) standard employee benefits generally made available to all employees, standard employee offer letters and Confidential Information
Agreements (as defined below), (ii) standard director and officer indemnification agreements approved by the board of directors of the
Companies, (iii) the purchase of shares of the Companies’ capital stock, in each instance, approved in the written minutes of the
board of directors (previously provided to the Purchasers or their respective counsel), and (iv) the Transaction Documents, there are
no agreements, understandings or proposed transactions between the Companies and any of its officers, directors, consultants or Key Employees,
or any Affiliate thereof.

 

(b) Other
than as disclosed is Section ‎5.11(b) of the Disclosure Schedule, the Companies are not indebted, directly or indirectly, to any of
its directors, officers or employees or to their respective spouses or children or to any Affiliate of any of the foregoing, other than
in connection with expenses or advances of expenses incurred in the ordinary course of business or employee relocation expenses and for
other customary employee benefits made generally available to all employees. None of the Companies’ directors, officers or employees,
or any members of their immediate families, or any Affiliate of the foregoing are, directly or indirectly, indebted to the Companies or,
have any (i) material commercial, industrial, banking, consulting, legal, accounting, charitable or familial relationship with any of
the Companies’ customers, suppliers, service providers, joint venture partners, licensees and competitors, (ii) direct or indirect
ownership interest in any firm or corporation with which the Companies are affiliated or with which the Companies have a business relationship,
or any firm or corporation which competes with the Companies.

 

5.12 Rights
of Registration and Voting Rights. The Companies are not under any obligation to register under the Securities Act any of its currently
outstanding securities or any securities issuable upon exercise or conversion of its currently outstanding securities. Except as contemplated
in the Voting Agreement, no stockholder of the Company has entered into any agreements with respect to the voting of capital shares of
the Companies.

 

5.13 Property.
The property and assets that the Companies own are free and clear of all mortgages, deeds of trust, liens, loans and encumbrances, except
for statutory liens for the payment of current taxes that are not yet delinquent and encumbrances and liens that arise in the ordinary
course of business and do not materially impair the Companies’ ownership or use of such property or assets. With respect to the
property and assets it leases, the Companies are in compliance with such leases and holds a valid leasehold interest free of any liens,
claims or encumbrances other than those of the lessors of such property or assets. The Companies do not own any real property.

 

    11

     

    

 

5.14 Financial
Statements. The Companies have delivered to the Purchaser their unaudited financial statements for the fiscal year ended December
31, 2019 and its unaudited financial statements (including balance sheet, income statement and statement of cash flows) as of June 30,
2020 (the “Balance Sheet Date”) and for the six-month period ended on the Balance Sheet Date (collectively, the “Financial
Statements”). The Financial Statements have been prepared in accordance with international financial reporting standards (“IFRS”)
applied on a consistent basis throughout the periods indicated. The Financial Statements fairly present in all material respects the financial
condition and operating results of the Company as of the dates, and for the periods, indicated therein, subject in the case of the unaudited
Financial Statements to normal year-end audit adjustments. Except for the Stockholders Loan, and except as disclosed in Section ‎5.14
of the Disclosure Schedule, the Companies have no liabilities or obligations, contingent or otherwise, other than (i) liabilities
incurred in the ordinary course of business subsequent to the Balance Sheet Date; (ii) obligations under contracts and commitments
incurred in the ordinary course of business; and (iii) liabilities and obligations of a type or nature not required under IFRS to be reflected
in the Financial Statements, which, in all such cases, individually and in the aggregate would not exceed $100,000. The Companies maintain
and will continue to maintain a standard system of accounting established and administered in accordance with IFRS.

 

5.15 Changes.
Since the Balance Sheet Date there have been no events or circumstances of any kind that have or could reasonably be expected to result
in a Material Adverse Effect.

 

5.16 Employee
Matters.

 

(a) To
the Companies’ knowledge, none of its employees is obligated under any contract (including licenses, covenants or commitments of
any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would materially
interfere with such employee’s ability to promote the interest of the Companies or that would conflict with the Companies’
business. Neither the execution or delivery of the Transaction Agreements, nor the carrying on of the Companies’ business by the
employees of the Companies, nor the conduct of the Companies’ business as now conducted and as presently proposed to be conducted,
will, conflict with or result in a breach of the terms, conditions, or provisions of, or constitute a default under, any contract, covenant
or instrument under which any such employee is now obligated.

 

(b) The
Companies are not delinquent in payments to any of its employees, consultants, or independent contractors for any wages, salaries, commissions,
bonuses, or other direct compensation for any service performed for it to the date hereof or amounts required to be reimbursed to such
employees, consultants or independent contractors. The Companies have complied in all material respects with all applicable state and
federal equal employment opportunity laws and with other laws related to employment, including those related to wages, hours, worker classification
and collective bargaining. The Companies have withheld and paid to the appropriate governmental entity or is holding for payment not yet
due to such governmental entity all amounts required to be withheld from employees of the Companies and are not liable for any arrears
of wages, taxes, penalties or other sums for failure to comply with any of the foregoing.

 

(c) To
the Companies’ knowledge, no Key Employee intends to terminate employment with the Company or is otherwise likely to become unavailable
to continue as a Key Employee. The Companies do not have a present intention to terminate the employment of any of the foregoing. The
employment of each employee of the Companies is terminable at the will of the Companies. Except as required by law, upon termination of
the employment of any such employees, no severance or other payments will become due. The Companies have no policy, practice, plan or
program of paying severance pay or any form of severance compensation in connection with the termination of employment services.

 

    12

     

    

 

(d) The
Companies have not made any representations regarding equity incentives to any officer, employee, director or consultant of the Companies.

 

(e) Section
‎5.16‎(e) of the Disclosure Schedule includes a list of all current and former employees of the Companies.

 

(f) To
the Companies’ knowledge, none of the Key Employees or directors of the Companies have been (i) subject to voluntary or involuntary
petition under the federal bankruptcy laws or any state insolvency law or the appointment of a receiver, fiscal agent or similar officer
by a court for his or her business or property; (ii) convicted in a criminal proceeding or named as a subject of a pending criminal proceeding
(excluding traffic violations and other minor offenses); (iii) subject to any order, judgment or decree (not subsequently reversed,
suspended, or vacated) of any court of competent jurisdiction permanently or temporarily enjoining him or her from engaging, or otherwise
imposing limits or conditions on his or her engagement in any securities, investment advisory, banking, insurance, or other type of business
or acting as an officer or director of a public company; or (iv) found by a court of competent jurisdiction in a civil action or
by the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated any federal or state securities,
commodities, or unfair trade practices law, which such judgment or finding has not been subsequently reversed, suspended, or vacated.

 

5.17 Tax
Returns and Payments. There are no federal, state, county, local or foreign taxes due and payable by the Companies which have not
been timely paid. There are no accrued and unpaid federal, state, country, local or foreign taxes of the Companies which are due, whether
or not assessed or disputed. There have been no examinations or audits of any tax returns or reports by any applicable federal, state,
local or foreign governmental agency. The Companies have duly and timely filed all federal, state, county, local and foreign tax returns
or other tax filings required to have been filed by it and there are in effect no waivers of applicable statutes of limitations with respect
to taxes for any year.

 

5.18 Insurance.
The Companies have in full force and effect insurance policies concerning such casualties as would be reasonable and customary for companies
like the Companies sufficient in amount (subject to reasonable deductions) to allow it to replace any of its properties that might be
damaged or destroyed.

 

5.19 Employee
Agreements. Each current and former employee, consultant and officer of the Companies has executed an agreement with the Companies
regarding confidentiality and proprietary information (the “Confidential Information Agreements”).

 

5.20 Permits.
The Companies have all franchises, permits, licenses and any similar authority necessary for the conduct of its business, the lack of
which could reasonably be expected to have a Material Adverse Effect. The Companies are not in default in any material respect under any
of such franchises, permits, licenses or other similar authority.

 

5.21 Amazon
Seller Code of Conduct and Policies. The Companies adhere to and comply with all Amazon policies, agreements, guidelines, and codes
of conduct applicable to the conduct of the Companies’ business (the “Amazon Policies”). The Companies have not
previously violated the Amazon Policies and have not received notice of any such violation.

 

5.22 Corporate
Documents. The Certificate of Incorporation and Bylaws of the Companies as of the date of this Agreement are in the form provided
to the Purchasers.

 

    13

     

    

 

5.23 Foreign
Corrupt Practices Act. Neither the Companies nor any of its directors, officers, employees or agents have, directly or indirectly,
made, offered, promised or authorized any payment or gift of any money or anything of value to or for the benefit of any “foreign
official” (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)),
foreign political party or official thereof or candidate for foreign political office for the purpose of (i) influencing any official
act or decision of such official, party or candidate, (ii) inducing such official, party or candidate to use his, her or its influence
to affect any act or decision of a foreign governmental authority, or (iii) securing any improper advantage, in the case of (i), (ii)
and (iii) above in order to assist the Companies or any of its affiliates in obtaining or retaining business for or with, or directing
business to, any person. Neither the Companies nor any of their directors, officers, employees or agents have made or authorized any
bribe, rebate, payoff, influence payment, kickback or other unlawful payment of funds or received or retained any funds in violation
of any law, rule or regulation. Neither the Company nor any of its officers, directors or employees are the subject of any allegation,
voluntary disclosure, investigation, prosecution or other enforcement action related to the FCPA or any other anti-corruption law (collectively,
“Enforcement Action”).

 

5.24 Data
Privacy. In connection with its collection, storage, use and/or disclosure of any information that constitutes “personal information,”
“personal data” or “personally identifiable information” as defined in applicable laws (collectively “Personal
Information”) by or on behalf of the Companies, the Companies are and have been in compliance with (i) all applicable laws (including,
without limitation, laws relating to privacy, data security, telephone and text message communications, and marketing by email or other
channels) in all relevant jurisdictions, (ii) the Companies’ privacy policies and public written statements regarding the Company’s
privacy or data security practices, and (iii) the requirements of any contract codes of conduct or industry standards, by which the Company
is bound. The Companies maintain and have maintained reasonable physical, technical, and administrative security measures and policies
designed to protect all Personal Information owned, stored, used, maintained or controlled by or on behalf of the Companies from and against
unlawful, accidental or unauthorized access, destruction, loss, use, modification and/or disclosure. The Companies are and have been,
to the Companies knowledge, in compliance in all material respects with all laws relating to data loss, theft and breach of security notification
obligations.

 

5.25 Export
Control Laws. The Companies have conducted all export transactions in accordance with applicable provisions of United States export
control laws and regulations, including the Export Administration Regulations, the International Traffic in Arms Regulations, the regulations
administered by the Office of Foreign Assets Control of the U.S. Treasury Department, and the export control laws and regulations of any
other applicable jurisdiction. Without limiting the foregoing: (a) the Companies have obtained all export licenses and other approvals,
timely filed all required filings and has assigned the appropriate export classifications to all products, in each case as required for
its exports of products, software and technologies from the United States and any other applicable jurisdiction; (b) the Companies are
in compliance with the terms of all applicable export licenses, classifications, filing requirements or other approvals; (c) there are
no pending or to the knowledge of the Companies, threatened claims against the Companies with respect to such exports, classifications,
required filings or other approvals; (d) there are no pending investigations related to the Companies’ exports; and (e) there are
no actions, conditions, or circumstances pertaining to the Company’s export transactions that would reasonably be expected to give
rise to any material future claims.

 

5.26 Regulatory
Approvals. The Companies possess all permits, licenses, registrations, certificates, authorizations, orders and approvals from the
appropriate federal, state or foreign regulatory authorities necessary to conduct their business, including all such permits, licenses,
registrations, certificates, authorizations, orders and approvals required by the FDA, EPA or any other federal, state or foreign agencies
or bodies engaged in the regulation of drugs, pharmaceuticals, medical devices, sanitation or biohazardous materials. The Companies have
not received any notice of proceedings relating to the suspension, modification, revocation or cancellation of any such permit, license,
registration, certificate, authorization, order or approval.

 

    14

     

    

 

5.27 Regulations.
The Companies are and have been in compliance with all applicable laws administered or issued by the FDA, EPA or any similar governmental
entity, including the Federal Food, Drug, and Cosmetic Act and all other laws regarding developing, testing, manufacturing, marketing,
distributing or promoting the products of the Companies, or complaint handling or adverse event reporting.

 

5.28 Disclosure.
The Companies have made available to the Purchaser all the information reasonably available to the Companies that the Purchaser has requested
for deciding whether to acquire the Primary Shares and Secondary Shares, including certain of the Company’s projections describing
its proposed business plan (the “Business Plan”). No representation or warranty of the Companies contained in this
Agreement, as qualified by the Disclosure Schedule, and no certificate furnished or to be furnished to Purchaser at the Closing contains
any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained herein or
therein not misleading in light of the circumstances under which they were made. The Business Plan was prepared in good faith; however,
the Companies do not warrant that it will achieve any results projected in the Business Plan. It is understood that this representation
is qualified by the fact that the Companies have not delivered to the Purchaser, and has not been requested to deliver, a private placement
or similar memorandum or any written disclosure of the types of information customarily furnished to purchasers of securities.

 

6. Representation
and Warranties of the Stockholders. Each of the Stockholders herby represents and warrants to the Purchaser, severally and not jointly,
acknowledging that Purchaser is entering the Agreement in reliance thereon, that:

 

6.1 Ownership.
The Stockholders own, beneficially and of record, and have good, valid marketable title to, all the Secondary Shares and no other person
owns, beneficially or of record the Secondary Shares. The Secondary Shares are free and clear of any liens, rights of first refusal, co-sale
rights, sale limitation or pre-emptive rights, except as a result of the transactions contemplated hereunder. No other person or entity
has any power or right, whether shared with any other person or entity, to dispose of the or direct the disposition, or to vote or direct
the voting of the Secondary Shares.

 

6.2 Authority.
The Stockholders have all requisite power and full legal right to execute and deliver this Agreement, and to perform all of their obligations
hereunder. This Agreement and the transactions contemplated hereby have been duly executed and delivered on the part of the Stockholders,
and constitute legal, valid and binding obligations, enforceable against each Stockholder in accordance with their terms.

 

6.3 No
Conflict. The execution, delivery and performance by the Stockholders of this Agreement and in accordance with its terms, and the
consummation by the Stockholders of the transactions contemplated hereby, will not result (with or without the giving of notice or the
lapse of time or both) in any conflict, violation, breach or default, or the creation of any lien, or the termination, acceleration, vesting
or modification of any right or obligation under or with respect to (a) any judgement, decree, order, statute, rule or regulation binding
on or applicable to the Stockholders; (b) any agreement or instrument to which the Stockholders are party or by which their assets are
bound.

 

6.4 Litigation.
The Stockholders are not aware of any claim, action or proceeding that is pending in any court or before any arbitrator against the Stockholders
with respect to the Secondary Shares or any other Common Stock of the Companies’ held by them.

 

    15

     

    

 

6.5 Upon
full receipt of the ADS Consideration (or such applicable ADSs as the Stockholders shall be entitled to upon achievement of the H1 2021
Milestone 2021 Annual Milestone), the Stockholders shall have no further rights in or to the Secondary Shares sold thereby.

 

6.6 Restricted
Securities. The Stockholders understands that the ADS Consideration has not been, and will not be, registered under the Securities
Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things,
the bona fide nature of the investment intent and the accuracy of the Stockholders’ representations as expressed herein. The Stockholders
understands that the ADS Consideration is “restricted securities” under applicable U.S. federal and state securities laws
and that, pursuant to these laws, the Stockholders must hold the ADS Consideration indefinitely unless they are registered with the Securities
and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available.
The Stockholders acknowledge that the Purchaser has no obligation to register or qualify the ADS Consideration for resale. The Stockholders
further acknowledge that if an exemption from registration or qualification is available, it may be conditioned on various requirements
including, but not limited to, the time and manner of sale, the holding period for the ADS Consideration, and on requirements relating
to the Purchaser which are outside of the Stockholders control, and which the Purchasers are under no obligation and may not be able to
satisfy. The Stockholders understand that this offering is not intended to be part of the public offering, and that the Stockholders will
not be able to rely on the protection of Section 11 of the Securities Act.

 

6.7 Legends.
The Stockholders understand that the ADSs constituting the ADS Consideration may be notated with one or all of the following legends:

 

“THE SHARES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW
TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT
RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES
ACT OF 1933.”

 

(a) Any
legend set forth in, or required by, the other Transaction Agreements.

 

(b) Any
legend required by the securities laws of any state to the extent such laws are applicable to the Shares represented by the certificate,
instrument, or book entry so legended.

 

6.8 Purchase
Entirely for Own Account. This Agreement is made with the Stockholders in reliance upon the Stockholders’ representation to
the Purchaser, which by the Stockholders’ execution of this Agreement, the Stockholders hereby confirm, that the ADS Consideration
to be acquired by the Stockholders will be acquired for investment for the Stockholders’ own account, not as a nominee or agent,
and not with a view to the resale or distribution of any part thereof, and that the Stockholders have no present intention of selling,
granting any participation in, or otherwise distributing the same. By executing this Agreement, the Stockholders further represents that
the Stockholders do not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant
participations to such Person or to any third Person, with respect to any of the ADS Consideration.

 

    16

     

    

 

6.9 Accredited
Investor; Non U.S. Person; Investment Experience. The Stockholders acknowledge that they are able to fend for themselves, can bear
the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating
and understanding the merits and risks of the investment in the Purchaser. The Stockholders are either (i) an accredited investor as defined
in Rule 501(a) of Regulation D promulgated under the Securities Act, or (ii) a Non U.S. Person as defined under Regulation S promulgated
under the Securities Act. To the extent that the Stockholders are non U.S. Persons, Stockholders (x) are not acquiring the ADS Consideration
on account or benefit of any U.S. Person, (y) are not, at the time of execution of the Agreement, and will not be at the time of the issuance
of the ADS Consideration, in the United States and (z) are not a “distributor” (as defined in Regulation S promulgated under
the Securities Act).

 

6.10 Foreign
Investors. If the Stockholders are not a United States person (as defined by Section 7701(a)(30) of the Code), the Stockholders
hereby represent that they have satisfied themselves as to the full observance of the laws of its jurisdiction in connection with any
invitation to subscribe for the ADS Consideration or any use of this Agreement, including (i) the legal requirements within its jurisdiction
for the purchase of the ADS Consideration, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental
or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant
to the purchase, holding, redemption, sale, or transfer of the ADS Consideration. The Stockholders subscription and payment for and continued
beneficial ownership of the ADS Consideration will not violate any applicable securities or other laws of the Stockholders jurisdiction.

 

6.11 No
General Solicitation. The Stockholders have neither directly or indirectly, including, through a broker or finder (a) engaged
in any general solicitation, or (b) published any advertisement in connection with the offer and sale of the ADS Consideration.

 

7. Representations
and Warranties of the Purchaser. The Purchaser hereby represents and warrants to the Company that:

 

7.1 Authorization.
The Purchaser has full power and authority to enter into the Transaction Agreements. The Transaction Agreements to which the Purchaser
is a party, when executed and delivered by the Purchaser, will constitute valid and legally binding obligations of the Purchaser, enforceable
against such Purchaser in accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance and any other laws of general application affecting enforcement of creditors’ rights generally,
and as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies, or (b) to
the extent the indemnification provisions contained in the Investors’ Rights Agreement may be limited by applicable federal or state
securities laws.

 

7.2 Purchase
Entirely for Own Account. This Agreement is made with the Purchaser in reliance upon the Purchaser’s representation to the Companies,
which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Primary Shares and Secondary Shares
to be acquired by the Purchaser will be acquired for investment for the Purchaser’s own account, not as a nominee or agent, and
not with a view to the resale or distribution of any part thereof, and that the Purchaser has no present intention of selling, granting
any participation in, or otherwise distributing the same. By executing this Agreement, the Purchaser further represents that the Purchaser
does not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participations
to such Person or to any third Person, with respect to any of the Shares. The Purchaser has not been formed for the specific purpose of
acquiring the Primary Shares or the Secondary Shares.

 

7.3 Disclosure
of Information. The Purchaser has had an opportunity to discuss the Company’s business, management, financial affairs and the
terms and conditions of the offering of the Primary Shares with the Companies’ management. The foregoing, however, does not limit
or modify the representations and warranties of the Companies in Section ‎5 of this Agreement or the right of the Purchaser
to rely thereon.

 

    17

     

    

 

7.4 Restricted
Securities. The Purchaser understands that the Primary Shares and the Secondary Shares have not been, and will not be, registered
under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon,
among other things, the bona fide nature of the investment intent and the accuracy of the Purchaser’s representations as expressed
herein. The Purchaser understands that the Primary Shares and Secondary Shares are “restricted securities” under applicable
U.S. federal and state securities laws and that, pursuant to these laws, the Purchaser must hold the Primary Shares and Secondary Shares
indefinitely unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption
from such registration and qualification requirements is available. The Purchaser acknowledges that the Companies have no obligation to
register or qualify the Primary Shares, or the Secondary Shares for resale. The Purchaser further acknowledges that if an exemption from
registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and
manner of sale, the holding period for the Primary Shares and Secondary Shares, and on requirements relating to the Companies which are
outside of the Purchaser’s control, and which the Companies are under no obligation and may not be able to satisfy. The Purchaser
understands that this offering is not intended to be part of the public offering, and that the Purchaser will not be able to rely on the
protection of Section 11 of the Securities Act.

 

7.5 No
Public Market. The Purchaser understands that no public market now exists for the Primary Shares and Secondary Shares, and that the
Companies have made no assurances that a public market will ever exist for the Primary Shares and Secondary Shares.

 

7.6 Legends.
The Purchaser understands that the Primary Shares and Secondary Shares may be notated with one or all of the following legends:

 

“THE SHARES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW
TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT
RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES
ACT OF 1933.”

 

(a) Any
legend set forth in, or required by, the other Transaction Agreements.

 

(b) Any
legend required by the securities laws of any state to the extent such laws are applicable to the Shares represented by the certificate,
instrument, or book entry so legended.

 

7.7 Accredited
Investor; Non U.S. Person; Investment Experience. The Purchaser acknowledges that it is able to fend for itself, can bear the economic
risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating and understanding
the merits and risks of the investment in the Companies. The Purchaser is either (i) an accredited investor as defined in Rule 501(a)
of Regulation D promulgated under the Securities Act, or (ii) a Non U.S. Person as defined under Regulation S promulgated under the Securities
Act. To the extent that the Purchaser is a non U.S. Person, Purchaser (x) is not acquiring the Primary Shares or Secondary Shares on account
or benefit of any U.S. Person, (y) is not, at the time of execution of the Agreement, and will not be at the time of the issuance of the
Primary Shares, in the United States and (z) is not a “distributor” (as defined in Regulation S promulgated under the Securities
Act).

 

    18

     

    

 

7.8 Foreign
Investors. If the Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Code), the Purchaser hereby
represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to
subscribe for the Primary Shares or any use of this Agreement, including (i) the legal requirements within its jurisdiction for the
purchase of the Primary Shares and Secondary Shares, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any
governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may
be relevant to the purchase, holding, redemption, sale, or transfer of the Primary Shares or the Secondary Shares. The Purchaser’s
subscription and payment for and continued beneficial ownership of the Primary Shares and the purchase of the Secondary Shares will not
violate any applicable securities or other laws of the Purchaser’s jurisdiction.

 

7.9 No
General Solicitation. Neither the Purchaser, nor any of its officers, directors, employees, agents, stockholders or partners has either
directly or indirectly, including, through a broker or finder (a) engaged in any general solicitation, or (b) published any
advertisement in connection with the offer and sale of the Primary Shares and Secondary Shares.

 

7.10 Residence.
Purchaser’s office or offices or principal place of business is as identified in the preamble to this agreement.

 

8. Conditions
to the Purchasers’ Obligations at Closing. The obligations of Purchaser to purchase
Primary Shares and the Secondary Shares at the Closing are subject to the fulfillment, on or before such Closing, of each of the following
conditions, unless otherwise waived:

 

8.1 Representations
and Warranties. The representations and warranties of the Companies and the Stockholders contained in Section ‎5 and
Section ‎6 shall be true and correct in all respects as of such Closing.

 

8.2 Performance.
The Companies, Stockholders and Manager shall have performed and complied with all covenants, agreements, obligations and conditions contained
in this Agreement that are required to be performed or complied with by the Companies, Stockholders and the Manager on or before such
Closing.

 

8.3 Compliance
Certificate. The chief executive officer of the Companies’ shall deliver to the Purchaser at such Closing a certificate certifying
that the conditions specified in Sections ‎8.1 and ‎8.2 have been fulfilled.

 

8.4 Qualifications.
All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of any state
that are required in connection with the lawful issuance and sale of the Primary Shares and sale of the Secondary Shares pursuant to this
Agreement shall be obtained and effective as of such Closing.

 

8.5 Opinion
of Company Counsel. The Purchasers shall have received from counsel for the Companies, an opinion, dated as of the Closing, in the
form acceptable to the Purchaser.

 

8.6 Board
of Directors. As of the Closing, the authorized size of the Pro board of directors (the “Pro Board”) shall be three
(3), and the Pro Board shall be comprised of Mr. Eli Yoresh, Mr. Liron Carmel and a director designated by the Pro Stockholder. As of
the Closing, the authorized size of the Purex board of directors (the “Purex Board”) shall be three (3), and the Purex
Board shall be comprised of Mr. Eli Yoresh, Mr. Liron Carmel and a director designated by the Purex Stockholders.

 

    19

     

    

 

8.7 Indemnification
Agreement. The Companies shall have executed and delivered the Indemnification Agreements for each of the members of the Pro Board
and Purex Board respectively.

 

8.8 Investors’
Rights Agreement. The Companies and the Stockholders of the Companies shall have executed and delivered the the Investors’ Rights
Agreement for each of Pro and Purex.

 

8.9 Voting
Agreement. The Companies and the Stockholders shall have executed and delivered their respective Voting Agreement.

 

8.10 Restated
Certificate. The Companies shall have each adopted and filed their respective restated certificates with the Secretary of State of
California, in the form acceptable to the Purchaser (the “Restated Certificates”) on or prior to the Closing, which
shall continue to be in full force and effect as of the Closing.

 

8.11 Restated
Bylaws. The Companies’ shall have each amended their respective Bylaws on or prior to the Closing, in accordance with a form
acceptable to Purchaser (the “Restated Bylaws”).

 

8.12 Secretary’s
Certificate. The Secretary of the Company shall have delivered to the Purchasers at the Closing a certificate certifying (i) the Certificate
of Incorporation and Bylaws of the Companies as in effect at the Closing, (ii) resolutions of Pro Board and Purex Board approving the
Transaction Agreements and the transactions contemplated under the Transaction Agreements, and (iii) resolutions of the Stockholders of
the Companies approving the Restated Certificates and Restated Bylaws.

 

8.13 Employment
Agreement. The Manager shall have executed and entered the Employment Agreement with Pro on or prior to the Closing with such Employment
Agreement to be in effect as of the Closing.

 

8.14 Proceedings
and Documents. All corporate and other proceedings in connection with the transactions contemplated at the Closing and all documents
incident thereto shall be reasonably satisfactory in form and substance to Purchaser, and Purchaser (or its counsel) shall have received
all such counterpart original and certified or other copies of such documents as reasonably requested. Such documents may include good
standing certificates.

 

9. Conditions
of the Companies’ and Stockholder Obligations at Closing. The obligations of the Companies’ and the Stockholder to sell
the Primary Shares and Secondary Shares to the Purchaser at the Closing are subject to the fulfillment, on or before the Closing, of each
of the following conditions, unless otherwise waived:

 

9.1 Representations
and Warranties. The representations and warranties of the Purchaser contained in Section ‎6 shall be true and correct in
all respects as of such Closing.

 

9.2 Performance.
The Purchaser shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement
that are required to be performed or complied with by Purchaser on or before such Closing.

 

9.3 Qualifications.
All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of any state
that are required in connection with the lawful issuance and sale of the Primary Shares and sale of the Secondary Shares pursuant to this
Agreement shall be obtained and effective as of the Closing.

 

    20

     

    

 

9.4 Investors’
Rights Agreement. Purchaser shall have executed and delivered the Investors’ Rights Agreement for each of the Companies.

 

9.5 Voting
Agreement. Purchaser shall have executed and delivered the Voting Agreement for each of the Companies.

 

10. Indemnification.

 

10.1 Effectiveness;
Survival.

 

(a) Purchaser
has the right to fully rely upon all representations, warranties and covenants of the Companies and Stockholders (as applicable, severally
and not jointly, the “Indemnitor”) contained in or made pursuant to this Agreement and in the schedules attached hereto.
Unless otherwise set forth in this Agreement, the representations and warranties of the Companies and Stockholders contained in or made
pursuant to this Agreement shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf
of Purchaser.

 

(b) The
representations and warranties of the Companies and the Stockholders contained in or made pursuant to this Agreement shall survive the
execution and delivery of this Agreement and the Closing until the earlier of:

 

(c) immediately
prior to the consummation of a Deemed Liquidation Event (as such terms are defined under the Restated Certificates), or

 

(d) (1)
in case of Section 4.8 (Intellectual Property), until the 36th months anniversary of the Closing; (2) in case of Sections
‎5.1 (Organization), ‎5.2 (Capitalization), ‎5.4 (Authorization), ‎5.5 (Valid Issuance of Shares),
‎5.6 (Consents) and ‎5.9 (Compliance with Other Instruments) (the representations and warranties referred to in
this clause ‎(d), collectively, the “Fundamental Representations”), until the expiration of the applicable statute
of limitation period; and (3) other than as set forth in clause (1) and (2) above, the 24th months anniversary of the Closing
Date; in each case, with respect to any theretofore un-asserted claims as set forth in clause (c) below;

 

provided, however,
that no limitation shall apply to breach of any representation or warranty which constitutes fraud or willful misrepresentation by the
Companies (as the case may be) (“Fraud”). The applicable survival period shall be referred to, as applicable, as the
“Claims Period”.

 

(e) Except
for Fraud, the Companies and Stockholders shall not have any liability with respect to any breach of representation and warranty, unless
a claim is made hereunder prior to the expiration of the Claims Period for such representation and warranty, in which case such representation
and warranty shall survive as to that claim until the claim has been finally resolved.

 

(f) It
is the intention of the parties hereto that the Claims Periods supersede any statute of limitations applicable to the representations
and warranties, and this Section ‎(f) constitutes a separate written legally binding agreement among the parties hereto.

 

10.2 Indemnification.

 

(a) Indemnifiable
Losses. The Indemnitor shall indemnify Purchaser (including its shareholders, limited and general partners directors and officers)
(each, an “Indemnitee”) against, and hold each Indemnitee harmless from all claims, actions, suits, settlements, damages,
expenses (including, reasonable legal costs and expenses), losses, diminution of value, or costs sustained or incurred by such Indemnitees
(collectively, “Losses”) resulting from, or arising out of, a breach or misrepresentations of any of the Indemnitor’s
representations, warranties or covenants made in this Agreement, subject to the limitations in this Section ‎10.2. For the avoidance
of doubt, Indemnitors shall indemnify Indemnitee for losses on a joint and not several basis.

 

    21

     

    

 

(b) Limitations.
The Indemnitee’s right for indemnification hereunder is subject to the following conditions and limitations, notwithstanding anything
to the contrary in this Agreement, but in addition to any other limitation or condition contained herein; provided, however, that
no such limitation shall apply to Fraud:

 

(c) Other
than in respect of the Fundamental Representations, no Indemnitor shall be liable for any Loss, unless and until the aggregate of Losses
equal or exceeds US$50,000, in which case indemnification shall be made from the first dollar amount.

 

(d) Except
for Fraud, the Indemnitor’s liability shall be limited to the aggregate amount of the Investment Amount under the Agreement at the
Closing and the ADS Consideration payable by Purchaser to the Indemnitors, and each Indemnitee shall be entitled to receive the indemnifiable
Loss up to the sum of the Investment Amount as of the Closing and the ADS Consideration actually payable thereafter.

 

(e) Claims
Notice; Third Party Claims. In the event that an Indemnitee wishes to assert a claim for indemnification hereunder it shall give the
Indemnitor a prompt written notice thereof (a “Claims Notice”), which shall describe in reasonable detail the facts
and circumstances upon which the asserted claim for indemnification is based and thereafter keep the Indemnitor informed, in all material
respects, with respect thereto. In the event that such Claims Notice results from a third party claim against the Indemnitee, such Indemnitee
shall promptly upon becoming aware of the commencement of proceedings by such third party provide the Indemnitor with the Claims Notice
and the Indemnitor shall have the right to assume the defense thereof (at Indemnitor’s expense) with counsel mutually satisfactory
to the parties; provided, however, that the Indemnitees shall have the right to retain their own counsel, at the reasonable expense
of the Indemnitor, and within the indemnification limitations herein, if representation of all parties by the counsel retained by the
Indemnitor would be inappropriate due to actual or potential differing interests between the parties in such proceeding. Failure of the
Indemnitees to give prompt notice or to keep it informed, as provided herein, shall not relieve the Indemnitor of any of its obligations
hereunder, except to the extent that the Indemnitor is actually and materially prejudiced by such failure. The Indemnitor shall not be
liable nor shall it be required to indemnify or hold harmless the Indemnitee in connection with any settlement effected without its consent
in writing, which shall not be unreasonably withheld or delayed.

 

(f) Sole
Remedy. The indemnification provided by the Indemnitor hereunder and the enforcement of such indemnification shall be the exclusive
remedy available to the Indemnitees under this Agreement, other than for Fraud; provided that this provision does not limit the
right to seek specific performance, a restraining order or injunctive relief with respect to any provision of this Agreement.

 

11. Miscellaneous.

 

11.1 Survival
of Warranties. Unless otherwise set forth in this Agreement, the representations and warranties of the Company and the Purchasers
contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and each Closing and shall
in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf of the Purchasers or the Company.

 

    22

     

    

 

11.2 Successors
and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors
and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties
hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement,
except as expressly provided in this Agreement.

 

11.3 Governing
Law. This Agreement shall be governed by the internal law of the State of Israel, without regard to conflict of law principles that
would result in the application of any law other than the law of the State of Israel.

 

11.4 Counterparts.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.

 

11.5 Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing
or interpreting this Agreement.

 

11.6 Notices.

 

(a) General.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given
upon the earlier of actual receipt, or (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail during
normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next business day,
(c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business
day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written
verification of receipt. All communications shall be sent to the respective parties at their address as set forth on the signature page
or in the preamble to this Agreement, or to such e-mail address or address as subsequently modified by written notice given in accordance
with this Section ‎11.6.

 

11.7 No
Finder’s Fees. Each party represents that it neither is nor will be obligated for any finder’s fee or commission in connection
with this transaction. The Companies agrees to indemnify and hold harmless Purchaser from any liability for any commission or compensation
in the nature of a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against
such liability or asserted liability) for which the Companies or any of its officers, employees or representatives is responsible.

 

11.8 Fees
and Expenses. Each party to this Agreement shall bear the cost of their own respective legal fees and expenses.

 

11.9 Attorneys’
Fees. If any action at law or in equity (including, arbitration) is necessary to enforce or interpret the terms of any of the Transaction
Agreements, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition
to any other relief to which such party may be entitled.

 

11.10 Amendments
and Waivers. Any term of this Agreement may be amended, terminated or waived only with the written consent of the Companies, Stockholders
and Purchaser. Any amendment or waiver effected in accordance with this Section ‎11.10 shall be binding upon the Purchaser
and each transferee of the Primary Shares or Secondary Shares, each future holder of all such securities, the Stockholders and the Companies.

 

    23

     

    

 

11.11 Severability.
The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.

 

11.12 Delays
or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon any breach
or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting
party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach
or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default
theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any
breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must
be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement
or by law or otherwise afforded to any party, shall be cumulative and not alternative.

 

11.13 Entire
Agreement. This Agreement (including the Exhibits hereto), the Restated Certificates, Restated Bylaws and the other Transaction Agreements
constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other
written or oral agreement relating to the subject matter hereof existing between the parties are expressly canceled.

 

11.14 Corporate
Securities Law. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF
CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF THE SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION
THEREFOR PRIOR TO THE QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM THE QUALIFICATION BY SECTION 25100, 25102
OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON THE QUALIFICATION
BEING OBTAINED UNLESS THE SALE IS SO EXEMPT.

 

11.15 Termination
of Closing Obligations. Purchaser shall have the right to terminate its obligations to complete the Closing if prior to the occurrence
thereof, any of the following occurs:

 

(a) the
either of the Companies consummates a Deemed Liquidation Event (as defined in the Restated Certificate);

 

(b) the
closing of an initial public offering of either of the Companies, in which case the Purchaser may terminate their obligations hereunder
immediately prior to, or contingent upon, such closing; or

 

(c) either
of the Companies (i) applies for or consents to the appointment of a receiver, trustee, custodian or liquidator of itself or substantially
all of its property, (ii) becomes subject to the appointment of a receiver, trustee, custodian or liquidator of itself or substantially
all of its property, (iii) makes an assignment for the benefit of creditors, (iv) institutes any proceedings under the United States Bankruptcy
Code or any other federal or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors
generally, or files a petition or answer seeking reorganization or an arrangement with creditors to take advantage of any insolvency law,
or files an answer admitting the material allegations of a bankruptcy, reorganization or insolvency petition filed against it, or (v)
becomes subject to any involuntary proceedings under the United States Bankruptcy Code or any other federal or state bankruptcy, reorganization,
receivership, insolvency or other similar law affecting the rights of creditors generally, when proceeding is not dismissed within thirty
(30) days of filing, or have an order for relief entered against it in any proceedings under the United States Bankruptcy Code.

 

11.16 Dispute
Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the competent courts of the State
of Israel and to the jurisdiction of Tel-Aviv courts for the purpose of any suit, action or other proceeding arising out of or based upon
this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the
state courts of Tel-Aviv, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit,
action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is
exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue
of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.

 

[Signature Page Follows]

 

    24

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first written above.

 

	 	SMART REPAIR PRO, INC.:
	 	 
	 	By:	/s/ Julia Gerasimova
	 	Name:  	Julia Gerasimova
	 	Title:	Owner
	 	 	 
	 	PUREX, INC.:
	 	 
	 	By:	/s/ Galit Mccord
	 	Name:	Galit Mccord
	 	Title:	Owner

 

     

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first written above.

 

	 	PURCHASER:
	 	 
	 	MEDIGUS LTD.
	 	 
	 	By:	/s/ Eli Yoresh
	 	Name:  	Eli Yoresh
	 	Title:	Chairman

 

     

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first written above.

 

	 	STOCKLHOLDERS:
	 	 
	 	JULIA GERASIMOVA
	 	 
	 	/s/ Julia Gerasimova
	 	 
	 	GALIT MCCORD
	 	 
	 	/s/ Galit Mccord
	 	 
	 	SOLY HACMON
	 	 
	 	/s/ Soly Hacmon
	 	 
	 	MANAGER:
	 	 
	 	VICKY HACMON
	 	 
	 	/s/ Vicky Hacmon

 

     

     

    

 

EXHIBITS AND SCHEDULES

 

	Schedule 1	SCHEDULE OF STOCKHOLDERS
	Exhibit A	DISCLOSURE SCHEDULE

 

     

     

    

 

SCHEDULE 1

 

Schedule of Stockholders

 

[***]

 

     

     

    

 

EXHIBIT A

 

Disclosure Schedule

 

[***]

 

 

30Exhibit 10.3

 

AMENDMENT NO.
1 TO COMMON STOCK PURCHASE AGREEMENT

 

This Amendment No. 1 (“Amendment”)
is entered into on this 22nd day of June 2021, by and between Smart Repair Pro, Inc., a private corporation incorporated under
the laws of the State of California (“Pro”), Purex Inc., a corporation incorporated under the laws the State of California
(“Purex”)(Pro together with Purex, the “Companies”), the undersigned stockholders of the Companies
(the “Pro Stockholder”, the “Purex Stockholders” respectively, and together the “Stockholders”)
and Vicky Hacmon, ID 033847799 of 112 Rokach Street, Ramat Gan, Israel (the “Manager”) on the one hand, and Medigus
Ltd., a public company incorporated under the laws of the State of Israel of 7A Industrial Park, P.O. Box 3030, Omer, 8496500 Israel (the
“Purchaser”) on the other hand.

 

Capitalized terms used but
not defined herein shall have the meaning ascribed to them under the Agreement (as defined below)

 

WHEREAS, the Parties
have previously entered into that certain Common Stock Purchase Agreement, dated as of October 8, 2020 (the “Agreement”);

 

WHEREAS, the Parties
wish to amend the Agreement with respect to the terms expressly stated in this Amendment and regulate their relationship in accordance
to the terms and conditions set forth herein.

 

NOW, THEREFORE, the Parties hereby agree as
follows:

 

		1.	Section 1.1(a) of the Agreement shall be amended in its entirety to read as follows:

 

“Companies
Valuation. The valuation used for the purpose of determining the purchase price for the Pro Common Stock and the Purex Common Stock
(as each are defined herein), shall be calculated on a joint basis, and shall be equal to; (A) the Companies consolidated seller discretionary
earnings, calculated as the Companies EBITDA (as approved by the Companies accountants for the period ended December 31, 2020 in accordance
with generally accepted accounting principles, or the “Determination Period”), plus general and administrative
expenses (including Manager’s compensation expenses) and research and development expenses relating to the development of new products
incurred during the Determination Period (the “SDE”); multiplied by (B) 3.5; minus (C) the outstanding
Stockholders Loan (as defined herein)(the “Companies Valuation”). The Companies Valuation shall be allocated among
the Companies such that Pro’s valuation shall equal 88% of the Companies Valuation (the “Pro Portion” and the
“Pro Valuation” respectively) and Purex’s valuation shall be equal to 12% of the Companies Valuation (the “Purex
Portion” and the “Purex Valuation” respectively). The Companies target SDE for the annual period ended December
31, 2020 shall be $1,000,000 (the “SDE Target”).

 

		2.	Effective Date 

 

This
Amendment shall be in effect as of the date hereof and shall be attached to the Agreement and become an integral part thereof. 

 

		3.	Reservation of Terms 

 

Except
as expressly stated in this Amendment all other terms in the Agreement shall remain unchanged unless specifically amended in accordance
with the terms of the Agreement.

 

- Signature Pages Follow -

 

     

     

    

 

IN WITNESS
WHEREOF, the parties have caused their duly authorized representatives to execute this Amendment
as of the day and year first above written.

 

	 	COMPANIES:
	 	 	 
	 	SMART REPAIR PRO, INC.:
	 	 	 
	 	By:	/s/ Julia Gerasimova
	 	Name: 	Julia Gerasimova
	 	Title: 	CEO
	 	 	 
	 	PUREX, INC.:
	 	 	 
	 	By:	
	 	Name: 	Galit Mccord
	 	Title: 	Owner

 

    2

     

    

 

IN WITNESS WHEREOF, the parties have caused
their duly authorized representatives to execute this Amendment as of the day and year first above written.

 

	 	PURCHASER:
	 	 	 
	 	MEDIGUS LTD.
	 	 	 
	 	By:	/s/ Eli Yoresh
	 	Name: 	
	 	Title:	

 

    3

     

    

 

IN WITNESS WHEREOF,
the parties have caused their duly authorized representatives to execute this Amendment as of the day and year first above written.

 

	 	STOCKLHOLDERS:
	 	 
	 	JULIA GERASIMOVA
	 	 
	 	/s/ Julia Gerasimova
	 	 
	 	GALIT MCCORD
	 	 
	 	/s/ Galit McCord
	 	 
	 	SOLY HACMON
	 	 
	 	/s/ Soly Hacmon
	 	 
	 	MANAGER:
	 	 
	 	VICKY HACMON
	 	 
	 	/s/ Vicky Hacmon

 

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}]]